What the FDA labels say about taking them together
Amiloride and trandolapril
Trandolapril's FDA label of October 31, 2025 names amiloride in its drug interactions section; amiloride's label does not name trandolapril itself but warns about its class (ACE inhibitors). The trandolapril label: “Use of potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.”
Check it at the source: the amiloride FDA label on DailyMed (effective May 5, 2023, Padagis US LLC); the trandolapril FDA label on DailyMed (effective October 31, 2025, Lupin Pharmaceuticals, Inc.).
What does the amiloride label say about trandolapril?
Amiloride's label does not name trandolapril itself; it warns about its class (ACE inhibitors):
Amiloride label, warningsThe risk of hyperkalemia may be increased when potassium-conserving agents, including amiloride HCl, are administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus. (See PRECAUTIONS, Drug Interactions .) Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities.
Amiloride label, drug interactionsDrug Interactions When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus, the risk of hyperkalemia may be increased.
Source: FDA drug label (amiloride hydrochloride), Padagis US LLC, effective May 5, 2023 (SPL set 2b70cf0c-45be-428f-b396-5001ed4e30fc), via openFDA; the full label on DailyMed
What does the trandolapril label say about amiloride?
Trandolapril label, drug interactionsUse of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
Source: FDA drug label (Trandolapril), Lupin Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8143a6cf-dadc-4ef7-a8db-d16d7150ad34), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amiloride | Trandolapril | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | High blood pressure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.190 per tablet 5 mg tablet | $0.157 per tablet 1 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once